EA202193065A1 - Фармацевтическая композиция, содержащая акситиниб - Google Patents

Фармацевтическая композиция, содержащая акситиниб

Info

Publication number
EA202193065A1
EA202193065A1 EA202193065A EA202193065A EA202193065A1 EA 202193065 A1 EA202193065 A1 EA 202193065A1 EA 202193065 A EA202193065 A EA 202193065A EA 202193065 A EA202193065 A EA 202193065A EA 202193065 A1 EA202193065 A1 EA 202193065A1
Authority
EA
Eurasian Patent Office
Prior art keywords
composition containing
pharmaceutical composition
axitinib
containing axitinib
usp
Prior art date
Application number
EA202193065A
Other languages
English (en)
Inventor
Мануэль Гаго Гильян
Рохит Кумар
Лисардо Альварес Фернандес
Original Assignee
Синтон Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Синтон Б.В. filed Critical Синтон Б.В.
Publication of EA202193065A1 publication Critical patent/EA202193065A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение относится к таблеточной композиции с немедленным высвобождением, содержащей форму IV акситиниба, характеризующуюся порошковой рентгенограммой, содержащей пики при около 8,9, 12,0, 14,6, 15,2, 15,7, 17,8, 19,1, 20,6, 21,6, 23,2, 24,2, 24,9, 26,1 и 27,50,1 2, при измерении с использованием Cu K1-излучения, и один или более фармацевтически приемлемых вспомогательных веществ, причем композиция демонстрирует скорость растворения от 40 до 70% в течение 30 мин при испытании в 900 мл 0,01н. соляной кислоты при рН 2,0 и температуре 37°C, 75 об/мин в аппарате II согласно USP.
EA202193065A 2019-05-09 2020-05-08 Фармацевтическая композиция, содержащая акситиниб EA202193065A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19173671 2019-05-09
PCT/EP2020/062840 WO2020225413A1 (en) 2019-05-09 2020-05-08 Pharmaceutical composition comprising axitinib

Publications (1)

Publication Number Publication Date
EA202193065A1 true EA202193065A1 (ru) 2022-03-02

Family

ID=66483852

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202193065A EA202193065A1 (ru) 2019-05-09 2020-05-08 Фармацевтическая композиция, содержащая акситиниб

Country Status (5)

Country Link
US (1) US20220226246A1 (ru)
EP (1) EP3965743A1 (ru)
JP (2) JP2022532540A (ru)
EA (1) EA202193065A1 (ru)
WO (1) WO2020225413A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4282415A1 (en) 2022-05-26 2023-11-29 Genepharm S.A. A stable tablet composition of axitinib

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
JP2008518904A (ja) 2004-11-02 2008-06-05 ファイザー・インク ６−［２−（メチルカルバモイル）フェニルスルファニル］−３−ｅ−［２−（ピリジン−２−イル）エテニル］インダゾールの多形体形態
NZ580126A (en) 2007-04-05 2012-03-30 Pfizer Prod Inc Crystalline forms of 6- [2- (methylcarbamoyl) phenylsulfanyl] -3-e- [2- (pyridin-2-yl) ethenyl] indazole suitable for the treatment of abnormal cell growth in mammals
MX2014003886A (es) 2011-09-30 2014-05-13 Pfizer Composiciones farmaceuticas de n-metil-2-[3-((e) 2-piridin-2-il-vinil)-1h-indazol-6-ilsulfanil]benzamida.
CZ2018150A3 (cs) * 2018-03-26 2019-04-10 Zentiva, K.S. Farmaceutické kompozice pro okamžité uvolňování léčiva

Also Published As

Publication number Publication date
EP3965743A1 (en) 2022-03-16
JP2024009815A (ja) 2024-01-23
US20220226246A1 (en) 2022-07-21
WO2020225413A1 (en) 2020-11-12
JP2022532540A (ja) 2022-07-15

Similar Documents

Publication Publication Date Title
AU2016378482A1 (en) Pharmaceutical composition comprising amorphous lenalidomide and an antioxidant
CN104173272B (zh) 一种异硫氰酸酯类化合物的缓释制剂
ES2435943T3 (es) Formulaciones de vildagliptina
KR20160101720A (ko) Azd9291을 포함하는 제약 조성물
JP6220485B2 (ja) コロイドビスマスペクチンを含有する分散製剤及びその製造方法
UA85359C2 (ru) Таблетка, содержащая гранулированный материал с kmd-3213
KR101272470B1 (ko) 레보드로프로피진을 포함하는 속효성과 지속성을 동시에 갖는 약제학적 조성물
ES2384333T3 (es) Composiciones farmacéuticas que tienen perfiles de disolución mejorados para fármacos poco solubles
NZ737561A (en) Oral composition of celecoxib for treatment of pain
ES2881317T3 (es) Composición farmacéutica que comprende sacubitrilo y valsartán
PH12019500154A1 (en) Formulation having improved ph-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof
EA202193065A1 (ru) Фармацевтическая композиция, содержащая акситиниб
HRP20161796T1 (hr) Farmaceutski pripravak za primjenu u tretmanu ili prevenciji deficijencije vitamina i minerala kod pacijenata podvrgnutih operaciji želučane premosnice
MX2013001637A (es) Composiciones farmaceuticas de liberacion controlada oral de blonanserina.
Suthar et al. Formulation and evaluation of fast dissolving tablets of ondansetron by solid dispersion in superdisintegrants
MX2017005163A (es) Composiciones de liberación prolongada de onapristona y métodos.
JP2021028326A (ja) レベチラセタムを含む錠剤
JP6440294B2 (ja) テルミサルタン含有フィルムコーティング錠剤
ES2922903T3 (es) Composición farmacéutica que comprende sales de lenvatinib
JP5644167B2 (ja) 溶出改善されたケトチフェン又はその塩を含有する固形製剤
EP2801350B1 (en) Pharmaceutical Formulations of Lacosamide
MY191983A (en) Pharmaceutical formulations comprising sodium palmitoyl-l-prolyl-l-prolyl-glycyl-l-tyrosinate and methods for preparing the same
MX2021011795A (es) Composición farmaceutica que comprende esomeprazol 0 sal farmaceuticamente aceptable del mismo y que tiene un perfil de liberación doble.
WO2020013776A3 (en) Synergistic effect of naproxen and a gastro protective agent for the treatment of pain and inflammation
WO2019203759A3 (en) Combinations of etodolac with h2 receptor antagonists for the treatment of pain and inflammation.